is a partner in the corporate and securities practice group and co-head of the North American healthcare and life sciences industry group. Randy structures and negotiates complex collaborations, mergers and acquisitions, divestitures, joint ventures, and corporate partnering and licensing transactions, as well as equity investments and royalty monetisation transactions for clients ranging from biotech start-ups to multinational pharmaceutical companies and private equity firms. He also handles technical contractual arrangements for drug discovery, development, manufacturing and supply, marketing and co-promotion, and outsourcing in the life sciences industry. Randy is a regular speaker at industry events on such topics as mergers and acquisitions, strategic alliances, and licensing and collaboration transactions. He has also been a guest lecturer at the Rutgers Business School MBA Biotechnology Commercialization Concentration.
Chambers and Partners make no representation or endorsement of the quality and services supplied
by companies or firms that may be found on this website. In no event will Chambers and Partners
be liable for any damages including, without limitation, indirect or consequential damages,
or any damages whatsoever arising from use or loss of use, data, or profits, whether in action
of contract, negligence or other tort action, arising out of or in connection with the use
of the website.